Biological Products, (No Diagnostic Substances)
| Institution | Shares | Value | Ownership % | Change | Filing Date |
|---|---|---|---|---|---|
| BlackRock, Inc. | 5.17M | $18.0M | 8.44% | -396.3K | 2026-06-30 |
| Millennium Management LLC | 4.44M | $15.0M | 7.25% | +1.01M | 2026-06-30 |
| Armistice Capital, LLC | 3.44M | $12.0M | 5.61% | -64.0K | 2026-06-30 |
| Vestal Point Capital, LP | 2.63M | $9.0M | 4.28% | -377.9K | 2026-06-30 |
| Vanguard Capital Management LLC | 2.35M | $8.0M | 3.83% | +62.4K | 2026-06-30 |
| Geode Capital Management, LLC | 1.33M | $4.0M | 2.17% | +280.5K | 2026-06-30 |
| Opaleye Management Inc. | 1.19M | $4.0M | 1.93% | +35.0K | 2026-06-30 |
| State Street Corp | 1.08M | $3.0M | 1.76% | +128.2K | 2026-06-30 |
| Two Sigma Investments, LP | 948.5K | $3.0M | 1.55% | -- | 2026-06-30 |
| Citadel Advisors LLC | 890.5K | $3.0M | 1.45% | +487.7K | 2026-06-30 |
